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To inform the level of attention to be given by antiretroviral 
therapy (ART) programs to HIV drug resistance (HIVDR), we 
used an individual-level model to estimate its impact on future 
AIDS deaths, HIV incidence, and ART program costs in sub–
Saharan Africa (SSA) for a range of program situations. We 
applied this to SSA through the Spectrum-Goals model. In a sit-
uation in which current levels of pretreatment HIVDR are over 
10% (mean, 15%), 16% of AIDS deaths (890 000 deaths), 9% of 
new infections (450 000), and 8% ($6.5 billion) of ART program 
costs in SSA in 2016–2030 will be attributable to HIVDR.
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The Joint United Nations Programme on HIV/AIDS (UNAIDS) 
has set the ambitious global goal of increasing the number of 
people on antiretroviral therapy (ART) who have viral load 
suppression, with the dual aim of eliminating AIDS as a public 
health threat and ending new infections by 2030 [1]. Since the 
start of the scale-up of ART in the early 2000s, levels of human 
immunodeficiency virus (HIV) drug resistance (HIVDR) have 
been increasing gradually [2, 3] and HIVDR has been shown 
to compromise the effect of commonly used drug regimens [4, 
5]. If levels of HIVDR are allowed to further increase, they may 
compromise the ability to reach the UNAIDS goal of 90% of all 
people taking ART having suppressed viral load. Moreover, high 
levels of HIVDR are likely an indication of gaps in ART service 
delivery (such as suboptimal retention on ART, poor popula-
tion-level adherence to ART, high levels of unknown treatment 
outcomes, and stock-outs of antiretroviral drugs) and signal the 
need for programmatic improvements. The actual and potential 
impact of HIVDR has not previously been estimated. We used 
a model of HIV/ART programs to estimate the impact of drug 
resistance from 2016 to 2030 in key outcomes of AIDS deaths, 
new infections, and ART program costs. Subsequently, using 
the Spectrum Goals model, we used these estimates of impact 
to estimate the absolute level of impact in sub–Saharan Africa 
as a whole [6].
METHODS
Modeling Approach
We use the HIV Synthesis Model, an individual-based simula-
tion model of HIV transmission, progression, and the effect of 
ART, considering specific drugs and resistance mutations. The 
model has been described in detail (eg, [7, 8]). For this project, 
we initially based the demographics of the population studied 
and HIV epidemic and ART program features around those 
for Malawi, although by sampling parameters relating to sex-
ual behavior, HIV testing, ART adherence, rate of treatment 
interruption, ART monitoring strategy, switch rate after first-
line regimen failure, we generated diverse situations likely to 
reflect a range of settings in SSA with respect to aspects such as 
HIV prevalence, ART uptake, HIV incidence, and transmitted 
HIVDR. We restricted attention to situations (ie, model runs) 
in which HIV prevalence was between 8%–30% in 1999 and 
between 8%–25% in 2004, and also to those in which the level 
of HIVDR amongst ART-naive treatment initiators was below 
20% in 2014, as evidence based on data to this date suggest that 
levels are below this [9–11].
For each setting situation generated, we look at the projected 
outcomes from 2016 to 2030 under the assumption of (1) no 
change in the rates of resistance acquisition and transmission 
(indicated as “with HIVDR” scenario in Table 1), and (2) a hypo-
thetical (ie, counterfactual) scenario in which resistant virus 
disappears in those in whom it is present (leaving all people 
with drug-sensitive virus only) and there is no new acquisition 
or transmission of resistant virus (“without further HIVDR” 
scenario). We assume that from 2016, viral load monitoring has 
been introduced (using the World Health Organization (WHO) 
criteria of a confirmed value >1000 copies/mL to define failure 
[12]), that efavirenz with tenofovir and emtricitabine/lamivu-
dine remains the first-line regimen for the duration, with ataza-
navir plus zidovudine and emtricitabine or lamivudine used 
in second-line regimens, and darunavir plus dolutegravir plus 
tenofovir plus emtricitabine or lamivudine as third-line. The 
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rate of switching to a second-line regimen after first-line failure 
is increased from 0.05 to 0.2 per 3 months before 2016, to 0.5 
per 3 months after 2017. This was done so that we could look 
at the impact of drug resistance in the context of close to an 
optimal switching strategy—our estimates of health impact are 
conservative in this respect. We present the median and 90% 
range over situations (model runs) for the impact of drug resis-
tance on HIV incidence, AIDS deaths, and ART program costs.
Having used the HIV Synthesis model to estimate the impact 
of HIVDR, we then extrapolated this to sub–Saharan Africa as 
a whole by applying the proportion of AIDS death, new infec-
tions, and ART costs attributable to HIVDR to the fast-track 
projected estimates of these obtained using the Spectrum Goals 
model [6].
Modeling of ART and HIVDR
HIVDR is modeled in terms of the presence or absence of 
mutations specific to the drugs in use. A distinction is made 
for each mutation as to whether it is present only in low abun-
dance and is thus transmissible. The probability of selection 
of drug-resistant virus among people on ART is determined 
by the number of active drugs in the regimen (determined by 
the presence of relevant resistance mutations), viral load, and 
the individuals’ current ART adherence. Mutations acquired 
while on ART are lost from majority virus (at a muta-
tion-specific rate) after the drug selecting for it is discon-
tinued, although these mutations remain in minority virus. 
Mutations present in minority virus reemerge in majority 
virus when 1 of the corresponding drugs is started. The prob-
ability of transmission of HIV from a condomless sex partner 
depends on the viral load in the source partner. The presence 
of drug resistance in in the partner does not directly influence 
the risk of transmission, only via any effect on viral load. For a 
newly infected person, the probability that the source partner 
has resistant virus in the majority circulating virus is deter-
mined by the prevalence of resistance among those with HIV 
having condomless sex. Not all resistance mutations present 
in majority virus in the source partner are established in the 
circulating virus of the newly infected person. The proba-
bility of transmission of drug resistance mutations is muta-
tion-specific. Once a virus with a mutation is transmitted and 
established in the new host, there is a tendency for a loss of 
drug-resistant mutation from majority virus over time; again, 
mutation-specific. A series of comparisons of model outputs 
with observed data for a range of ART-related variables are 
shown in the Supplementary Material.
Table 1. Impact of HIVDR Between 2016–2030a 
Scenario Until 
2030
Of those on ART, Percent 
With Viral Load <1000 
copies/ 
mL
AIDS Deaths (per 
year)b
HIV Incidence 
(adults 15–49)/100 
PY
Cost of First- 
Line ART 
($)b,c,d
Cost of Second- 
Line ART ($)b,c,d
Cost of Third- 
Line ART ($)b,c,d Overall ART Cost ($)b,c,d
Current level of PDR <10% (mean ~ 5.7%)
(1) With 
HIVDR
89% 16 000 0.19 50M 21M 1.0M 72M
(2) Without 
further 
HIVDR
95% 14 000 0.17 55M 12M 0.7M 68M
Effect of 
HIVDR
6%
Median 6% (5%–7%) 
lower viral suppres-
sion rate in those 
on ART
13%
Median 12% 
(3%–23%)
attributable to 
HIVDR
7%
Median 8% 
(0%–23%)
HIV incidence 
attributable to 
HIVDR
Lower cost 
of 1st-line 
drugs
Higher cost 
of 2nd-line 
drugs
Higher cost 
of 3rd-line 
drugs
6%
Median 6% (2%–9%) 
of ART costs attrib-
utable to HIVDR
Current level of PDR ≥10% (mean ~ 15%)
(1) With 
HIVDR
85% 26 000 0.48 71M 38M 2.0M 111M
(2) Without 
further 
HIVDR
93% 22 000 0.43 79M 22M 1.4M 102M
Effect of 
HIVDR
8%
Median 8% (6%–10%) 
lower viral suppres-
sion rate in those 
on ART
16%
Median 16% 
(7%–25%) 
attributable  
to HIVDR
9%
Median 9% 
(0%–26%)
HIV incidence 
attributable to 
HIVDR
Lower cost 
of 1st-line 
drugs
Higher cost 
of 2nd-line 
drugs
Higher cost 
of 3rd-line 
drugs
8%
Median 8% (4%–11%)
of ART costs attribut-
able to HIVDR
Abbreviations: ART, antiretroviral therapy; HIV, human immunodeficiency virus; HIVDR, HIV drug resistance; PDR, pretreatment HIV drug resistance; PY, person-years.
aMean and, for effect of drug resistance, median; 90% range over model runs /situations. This is the projected average impact in the context of low income settings in sub–Saharan Africa 
with an adult population size of 10 million.
bIn context of country with adult population size of 10 million.
cDiscounted at 3% per year.
dCosts of antiretroviral drugs (including 20% for supply chain) for first-line $120, second-line $343, and third-line $962. Other unit costs are shown in Supplementary Methods.
1364 • JID 2017:215 (1 May) • BRIEF REPORT
RESULTS
We generated 2500 HIV epidemic/program situations in total. 
The characteristics of these situations in 2015 are reported as the 
median (5%–95% range): HIV prevalence (median, 8%; range 
4%–17%), HIV incidence (0.36 per 100 person years; range, 
0.12–1.26), proportion diagnosed (median, 86%; range, 68%–
93%), proportion on ART (median, 64%; range, 47%–78%).
Table 1 shows the outcomes projected for 2016–2030 for sce-
narios “with HIVDR” and “without further HIVDR.” Table 1 
also shows the percentage or absolute difference between these 
scenarios, which indicates the impact that HIVDR is projected 
to have over 2016–2030. This is shown separately in the context 
of setting situations with current level of pretreatment HIVDR 
(PDR) <10% and over 10%. In the former case, we estimate a 
6% lower viral suppression rate in those on ART, 13% higher 
number of AIDS deaths per year, 7% higher HIV incidence, 
and 6% higher ART costs, which are all attributable to HIVDR. 
In settings with current level of PDR ≥10%, an 8% lower viral 
suppression rate in those on ART, 16% higher number of AIDS 
deaths per year, 9% higher HIV incidence, and 8% higher ART 
costs are attributable to HIVDR. The median and 90% range 
over model runs presented conveys the uncertainty and vari-
ability across settings in these estimates of attribution.
Table  2 shows the projected average impact of HIVDR on 
AIDS deaths, new infections, and ART costs in sub–Saharan 
Africa between the present and 2030 using the Spectrum 
Goals fast-track modeling. Results indicate that in a situation 
where pretreatment drug-resistance levels are generally below 
10%, there is still a substantial impact of drug resistance, being 
responsible for an estimated 710 000 AIDS deaths, 380 000 new 
infections, and $5.0 billion extra ART costs by 2030. If levels 
of pretreatment drug resistance are over 10%, the impact is 
greater, with an estimated 890 000 AIDS deaths, 450 000 new 
infections, and $6.5 billion extra ART costs by 2030 attributable 
to HIVDR.
DISCUSSION
Recently, elevated levels of non-nucleoside reverse transcrip-
tase inhibitor (NNRTI) drug resistance among ART-naive 
individuals have been observed in several low- and middle-in-
come countries, including Angola (14%), Botswana (8%), Cuba 
(8%), Mexico (10%), Papua New Guinea (16%), and South Africa 
(14%) [9–11]. The levels of NNRTI resistance reach almost 40% 
among ART starters with prior antiretroviral exposure [9, 11]. 
Our estimates indicate that, even in settings where pretreatment 
HIVDR levels are relatively lower (<10%), resistant virus is nev-
ertheless responsible for a significant extra burden of new AIDS 
deaths and additional costs. Results underscore the need for 
countries to follow WHO recommendations to both monitor 
levels of HIVDR and ART program factors (or early warning 
indicators of HIVDR) associated with its emergence, and make 
any necessary program changes to reduce the rate with which 
resistance emerges, accumulates, and is subsequently transmit-
ted [12–14]. We convey uncertainty and variability between 
settings in the impact of HIVDR through our 90% range over 
model runs. These bounds suggest that there is more uncer-
tainty and variability around the impact of HIVDR on new 
infections than around the impact on AIDS deaths and costs.
It is important to emphasize that our estimates of the impact 
of resistance are based on there being no change in the regi-
mens in use or introduction of baseline drug-resistance test-
ing. While our modeling shows the importance and impact of 
HIVDR in determining program outcomes if this current situ-
ation continues, it does not address the practical questions of 
what the response should be in countries to finding high lev-
els of pretreatment HIVDR and what level of HIVDR should 
trigger a public health response. Previous work has suggested a 
key role for introducing viral load monitoring, if not available 
[8]. In addition, increasing the frequency of viral load moni-
toring and using a lower threshold to define failure could be 
another response to high levels of transmitted drug resistance. 
Other potential future options include transitioning from efa-
virenz-based to dolutegravir-based first-line regimens, and pos-
sibly in some areas the use of individual-level drug resistance 
testing before or soon after the start of ART.
Although we show that drug resistance is a serious concern, 
it should not be used as a reason against expanding ART use to 
all individuals infected with HIV both for treatment and pre-
vention, as is now recommended by WHO [12]. Modeling has 
Table 2. Projected Impact of HIVDR on AIDS Deaths, New Infections, and ART Costs in Sub–Saharan Africa 2016–2030.a 
AIDS Deaths New Infections ART Costs
With HIVDR (Fast-track projections) 5.6 million 5.1 million $ 83 billion
Current level of PDR <10%
Percentage attributable to HIVDR 13% 7% 6%
Amount attributable to HIVDR 710,000 380 000 $5.0 billion
Current level of PDR ≥10%
Percentage attributable to HIVDR 16% 9% 8%
Amount attributable to HIVDR 890 000 450 000 $6.5 billion
Abbreviations: HIV, human immunodeficiency virus; HIVDR, HIV drug resistance; PDR, pretreatment HIV drug resistance.
aUsing the Spectrum Goals Model estimates [6] by applying the impact of drug resistance as estimated using the HIV Synthesis Model.
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shown that the benefits of “treat all” far outweigh the poten-
tial risks of HIVDR; in fact, while we should expect to see an 
increased proportion of ART initiators with drug-resistant 
virus, overall HIV incidence is predicted to decline [7, 15].
It is important to note in studying Table 1 that any compar-
isons across the <10% and >10% pretreatment HIVDR situa-
tions should be interpreted with caution, as such comparisons 
not only reflect the effect of HIVDR but also the presence of 
confounding. For example, settings in which population-level 
adherence to ART is lower tend to have higher levels of pretreat-
ment HIVDR, but there are also direct effects of adherence on 
mortality, viral suppression, and HIV incidence, which are not 
mediated by drug resistance. Thus, there is confounding by the 
common cause of poor adherence. A further caveat is that the 
estimates in Table 1 are based on adults only. While fewer chil-
dren are being infected, among HIV-positive children there are 
often high levels of acquired and transmitted drug resistance. In 
this respect, our results underestimate the full impact of HIVDR.
In summary, our results indicate that HIVDR inevitably 
causes attenuation of the potential full health benefits of ART 
and adds cost to the programs. While we cannot remove drug 
resistance completely, we can take measures to minimize 
its impact on health and ART program costs. To achieve the 
UNAIDS targets of 90-90-90 by 2020 and the elimination of 
AIDS as a public health threat by 2030, not only do millions of 
people need to be started and retained on ART, but the qual-
ity of service delivery in many countries needs be strengthened 
and routine HIVDR surveillance and response must become an 
integral part of ART programs.
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